Acalabrutinib plus rituximab for treating antiMAG mediated IgM peripheral neuropathy in WM

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=YNtWfFIisrw

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase II trial (NCT05065554) investigating the combination of acalabrutinib and rit...

Speaker: Jorge Castillo, Event: ASH 2023, Institution: Dana-Farber Cancer Institute, Format: Interview, Subject: Waldenström’s Macroglobulinemia, Subject: Lymphoma, Subject: Rare Diseases, Field: Treatment, Field: Trial Updates, Field: Immuno-Oncology, Medicines: BTK inhibitors, Medicines: Acalabrutinib, Medicines: Rituximab, Medicines: Antibodies, NCT05065554, combination therapy, anti-MAG, IgM, disability, peripheral neuropathy, WM
#############################